Human papillomavirus related cervical cancer and anticipated vaccination challenges in Ethiopia.

TeweldeTesfaye Gebremariam
Author Information
  1. TeweldeTesfaye Gebremariam: Department of Medical Microbiology and Immunology, College of Health Sciences, Mekelle University, Mekelle, Ethiopia.

Abstract

Cervical cancer is the leading cause of cancer deaths among women in Ethiopia. This may be due to the high prevalence of high-risk human papillomavirus (HR-HPV) genotypes in the population. So far, few studies have been done that showed the presence of HR-HPV genotypes. The HR-HPV-16, -18, -52, -56, -31 and -58 were the most common genotypes reported in Ethiopia. The introduction of HPV vaccines in Ethiopia is likely to go a long way in reducing cervical cancer deaths. However, there are few challenges to the introduction of the vaccines. The target population for HPV vaccination is at the moment not well-defined. Besides, the current HPV vaccines confer only type-specific (HPV-16 and -18) immunity, leaving a small proportion of Ethiopian women unprotected against other HR-HPV genotypes such as 52, 56, 31 and 58. Thus, future HPV vaccines such as the nanovalent vaccine may be more useful to Ethiopia as they will protect women against more genotypes.

Keywords

References

  1. Int J Equity Health. 2012 Dec 29;11:83 [PMID: 23273140]
  2. Gynecol Oncol. 2008 Sep;110(3 Suppl 1):S18-25 [PMID: 18653221]
  3. Obstet Gynecol. 2008 Jun;111(6):1380-7 [PMID: 18515522]
  4. Br J Cancer. 2007 May 7;96(9):1480-3 [PMID: 17437020]
  5. Infect Agent Cancer. 2010 Dec 30;5:26 [PMID: 21192803]
  6. Int J Cancer. 2004 Aug 20;111(2):278-85 [PMID: 15197783]
  7. J Natl Cancer Inst. 2006 Mar 1;98(5):303-15 [PMID: 16507827]
  8. Int J Cancer. 2007 Feb 1;120(3):650-5 [PMID: 17096345]
  9. J Med Virol. 2013 Feb;85(2):282-7 [PMID: 23160919]
  10. J Microbiol Biotechnol. 2008 Apr;18(4):788-94 [PMID: 18467878]
  11. Infect Dis Obstet Gynecol. 2009;2009:810596 [PMID: 20169094]
  12. Lancet. 2001 Oct 27;358(9291):1429-30 [PMID: 11705494]
  13. Int J Equity Health. 2011 Jun 30;10:27 [PMID: 21718495]
  14. AIDS. 2006 Nov 28;20(18):2381-3 [PMID: 17117025]
  15. Clin Infect Dis. 2005 Feb 1;40(3):451-7 [PMID: 15668870]
  16. Virology. 2005 Jun 20;337(1):76-84 [PMID: 15914222]
  17. Eur J Epidemiol. 2006;21(9):727-9 [PMID: 17072541]
  18. Gynecol Oncol. 2005 Dec;99(3 Suppl 1):S201-2 [PMID: 16419208]
  19. Trop Med Int Health. 2009 Oct;14(10):1287-302 [PMID: 19772550]
  20. N Engl J Med. 2003 Feb 6;348(6):518-27 [PMID: 12571259]
  21. Otolaryngol Pol. 2014 Sep-Oct;68(5):213-9 [PMID: 25283316]
  22. BMC Cancer. 2013 Jan 02;13:2 [PMID: 23282173]
  23. Infect Agent Cancer. 2011 Nov 14;6(1):20 [PMID: 22081870]
  24. Infect Agent Cancer. 2014 Feb 11;9(1):6 [PMID: 24517499]
  25. Virol J. 2011 Nov 10;8:514 [PMID: 22074103]
  26. Virology. 2010 May 25;401(1):70-9 [PMID: 20206957]
  27. Int J Cancer. 2007 Aug 1;121(3):621-32 [PMID: 17405118]
  28. Vaccine. 2007 Apr 20;25(16):3007-13 [PMID: 17292517]
  29. BMC Public Health. 2014 Jul 09;14:700 [PMID: 25004868]
  30. Drugs. 2010 Jun 18;70(9):1079-98 [PMID: 20518577]
  31. Int J Infect Dis. 2010 Sep;14(9):e810-4 [PMID: 20655263]
  32. Int J Cancer. 2003 Mar 1;103(6):803-9 [PMID: 12516102]
  33. Infect Agent Cancer. 2014 Oct 08;9(1):33 [PMID: 25320636]
  34. Int J Cancer. 2010 Dec 15;127(12):2893-917 [PMID: 21351269]
  35. Diagn Pathol. 2009 Sep 09;4:31 [PMID: 19740435]
  36. Ethiop Med J. 2015 Apr;53(2):65-74 [PMID: 26591294]
  37. BMC Infect Dis. 2010 Jan 26;10 :18 [PMID: 20102630]
  38. BMC Infect Dis. 2011 Jan 12;11:13 [PMID: 21226933]
  39. Best Pract Res Clin Obstet Gynaecol. 2011 Oct;25(5):565-74 [PMID: 21708487]
  40. J Virol. 2009 Oct;83(19):10085-95 [PMID: 19640991]
  41. Bull World Health Organ. 2008 Jun;86(6):488-90 [PMID: 18568279]
  42. Trop Med Int Health. 2010 Aug;15(8):890-3 [PMID: 20545913]
  43. Lancet. 2005 Sep 17-23;366(9490):991-8 [PMID: 16168781]
  44. Mem Inst Oswaldo Cruz. 2005 Feb;100(1):1-12 [PMID: 15867955]
  45. Indian J Med Res. 2009 Sep;130(3):341-7 [PMID: 19901444]
  46. PLoS One. 2013 Dec 20;8(12):e84519 [PMID: 24376818]

Word Cloud

Created with Highcharts 10.0.0EthiopiacancergenotypesHPVvaccineswomenpapillomavirusHR-HPVchallengesCervicaldeathsmaypopulation-18introductioncervicalvaccinationHumanleadingcauseamongduehighprevalencehigh-riskhumanfarstudiesdoneshowedpresenceHR-HPV-16-52-56-31-58commonreportedlikelygolongwayreducingHowevertargetmomentwell-definedBesidescurrentconfertype-specificHPV-16immunityleavingsmallproportionEthiopianunprotected52563158ThusfuturenanovalentvaccineusefulwillprotectrelatedanticipatedVaccination

Similar Articles

Cited By